Research antibodies are commonly used as reagents for detecting, measuring and purifying proteins in clinical diagnostics and life science research activities. From examining genetic characteristics and biological functions of cells and tissues to studying the complexities of diseases, antibodies play a critical role in driving scientific discoveries and medical innovation. Researchers rely on high-quality antibodies to understand disease pathology, develop and monitor new treatments, as well as for biomarker discovery, drug target identification and validation. Rising global burden of chronic diseases and growing demand for personalized healthcare have boosted the scope of biomedical research activities in recent years. Greater funding into R&D of new pharmaceuticals and expansion of biotechnology industry worldwide are expected to fuel demand for research antibodies going forward.
The global research antibodies market is estimated to be valued at US$ 3,785.5 Bn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Two key drivers expected to aid the growth of research antibodies market include growing adoption of targeted proteomics research and advancements in antibody engineering technologies. Targeted proteomic analysis uses mass spectrometry to map entire protein expression and interaction networks. It holds promise for precision medicine by facilitating development of biomarkers for early disease detection and personalized treatment responses. Similarly, recent technological advancements such as monoclonal antibody phage display libraries, synthetic antibody technologies and transgenic animals are allowing researchers to generate antibodies more efficiently and targeting multiple epitopes simultaneously. This is increasing the applications of antibodies in various disease diagnostic and cell biology studies. Growing pressure to lower healthcare costs through effective drug discovery and development processes will also drive continued investment in proteomics and antibody engineering research.
The research antibodies market is dominated by the primary antibodies segment, which held around 60% share of the overall market in 2024. Primary antibodies are directly used by end-users as they can recognize and bind specifically to antigens or epitopes without additional components like enzymes. They are widely utilized for applications such as western blotting, immunohistochemistry, and immunofluorescence, among others.
Political: The regulations surrounding the production and testing of research antibodies are becoming stricter to ensure safety and effectiveness. For example, the EU has strengthened Good Manufacturing Practice guidelines.
Economic: The global economy downturn due to the COVID-19 pandemic negatively impacted the research antibodies market. However, increasing R&D spending on drug development by biopharmaceutical companies is driving demand.
Social: Growing public-private investments to support basic biology research and the rise of precision medicine are boosting the market. Aging population has also led to higher disease incidence rates requiring newer drug therapies.
Technological: Advancements in monoclonal antibody production techniques like mammalian cell expression systems are helping manufacturers scale-up customized antibody production. Advent of rapid screening platforms is expediting the antibody discovery process.
The global Research Antibodies Market Growth is expected to witness high growth over the forecast period supported by increasing investments in life sciences research.
Asia Pacific is poised to be the fastest growing regional market during the analysis period attributed to growing Research & Development funding and increasing outsourcing of clinical trials and research projects to China and India by global pharmaceutical companies seeking to reduce costs. Furthermore, investments by regional governments to establish biotech clusters will further propel the regional market.
Key players operating in the research antibodies market are Zoetis Inc., Elanco Animal Health, MSD Animal Health, Benchmark Holdings, Phibro Animal Health Corporation, Intervet Inc., Norvartis, Merck Animal Health, Novartis AG, Pharmaq AS, AquaBounty Technologies, Alltech, Skretting, Nutreco, Biomin. Zoetis Inc. and Elanco Animal Health captured a major share of the market owing to their well recognized brands and wide global presence across key markets.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it